US Stock MarketDetailed Quotes

MIRM Mirum Pharmaceuticals

Watchlist
  • 50.040
  • -0.660-1.30%
Close Feb 14 16:00 ET
  • 50.040
  • 0.0000.00%
Post 16:52 ET
2.40BMarket Cap-24.06P/E (TTM)

About Mirum Pharmaceuticals Company

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Company Profile

SymbolMIRM
Company NameMirum Pharmaceuticals
Listing DateJul 18, 2019
Issue Price15.00
Founded2018
CEOMr. Christopher Peetz
MarketNASDAQ
Employees264
Fiscal Year Ends12-31
Address989 East Hillsdale Boulevard,Suite 300
CityFoster City
ProvinceCalifornia
CountryUnited States of America
Zip Code94404
Phone1-650-667-4085

Company Executives

  • Name
  • Position
  • Salary
  • Christopher Peetz
  • Director and Chief Executive Officer
  • 6.45M
  • Eric H. Bjerkholt
  • Chief Financial Officer
  • 4.34M
  • Dr. Joanne Quan, M.D.
  • Chief Medical Officer
  • --
  • Dr. Pamela Vig, PhD
  • Chief Scientific Officer
  • --
  • Peter Radovich
  • Chief Operating Officer and President
  • 2.37M
  • Lara Longpre, PhD
  • Chief Development Officer
  • --
  • Michael Grey
  • Chairman of the Board
  • 451.75K
  • Saira Ramasastry, M.Phil,M.S.
  • Independent Director
  • 411.75K
  • William Carl Fairey
  • Independent Director
  • 411.75K
  • Laura A. Brege
  • Independent Director
  • 426.75K
  • Timothy P. Walbert
  • Independent Director
  • 671.53K
  • Dr. Lon Cardon, PhD
  • Independent Director
  • 194.47K
  • Patrick J. Heron
  • Independent Director
  • 401.75K
  • Dr. Laurent Fischer, M.D.
  • Independent Director
  • 421.75K

Trending Stocks

Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More